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Summary
De novo lipogenesis is an energy-expensive process whose role in adult mammals is poorly understood. We generated
mice with liver-specific inactivation of fatty-acid synthase (FAS), a key lipogenic enzyme. On a zero-fat diet, FASKOL (FAS
knockout in liver) mice developed hypoglycemia and fatty liver, which were reversed with dietary fat. These phenotypes
were also observed after prolonged fasting, similarly to fasted PPAR-deficiency mice. Hypoglycemia, fatty liver, and
defects in expression of PPAR target genes in FASKOL mice were corrected with a PPAR agonist. On either zero-fat or
chow diet, FASKOL mice had low serum and hepatic cholesterol levels with elevated SREBP-2, decreased HMG-CoA
reductase expression, and decreased cholesterol biosynthesis; these were also corrected with a PPAR agonist. These
results suggest that products of the FAS reaction regulate glucose, lipid, and cholesterol metabolism by serving as endog-
enous activators of distinct physiological pools of PPAR in adult liver.Introduction
Primitive organisms exquisitely adapt gene expression to
changes in nutrients that are frequently accessible across a
single biological membrane. Complex organisms must balance
metabolic supply and demand through physiological systems
ensuring appropriate provision of substrates to tissues without
direct access to a nutrient source. In mammals, the liver inte-
grates nutrient intake and the delivery of carbohydrates and
lipids to peripheral tissues. Hepatocytes, exposed to dietary
signals (from portal blood flow) and systemic signals (from the
arterial blood supply), coordinate gene expression and main-
tain homeostasis (Jump and Clarke, 1999; Langhans 2003).
Abnormal hepatocyte function is central to common human
diseases including type 2 diabetes (characterized by excessive
hepatic glucose production), atherosclerosis (associated with
excessive production of atherogenic lipoproteins by the liver),
and steatohepatitis or fatty liver (commonly seen in obesity and
insulin resistance).
Hepatocytes assimilate carbohydrate and lipid signals in part
through PPARα, a member of the nuclear receptor superfamily
(Berger and Moller, 2002). PPARs first appeared about 280 mil-
lion years ago at the fish/mammal divergence (Latruffe and
Vamecq, 2000), providing a molecular mediator for adapting to
intermittent nutritional deprivation. PPARα stimulates the tran-
scription of genes critical for fatty-acid oxidation (Reddy, 2001)
and ketogenesis (Rodriguez et al., 1994). It also promotes glu-
coneogenesis through several mechanisms (Bernal-Mizrachi et
al., 2003; Koo et al., 2004), including the stimulation of hepatic
glycerol utilization (Patsouris et al., 2004). Highlighting the im-
portance of PPARα in managing energy stores, PPARα-defi-
cient mice develop hypoglycemia, hypoketonemia, and fattyCELL METABOLISM : MAY 2005 · VOL. 1 · COPYRIGHT © 2005 ELSEVIEliver when subjected to a prolonged fast (Kersten et al., 1999).
Fatty acids are thought to be the natural ligands for PPARα,
but the precise origin of these activators is unknown.
SREBPs (sterol regulatory element binding proteins) are an-
other class of proteins used by hepatocytes to coordinate car-
bohydrate and lipid metabolism (Horton et al., 2002). They re-
side in the ER and must be proteolytically cleaved in the Golgi
to yield forms that are transcriptionally active. There are two
predominant forms of SREBPs in animals, SREBP-1c, which
stimulates fatty-acid synthesis, and SREBP-2, which stimu-
lates cholesterol synthesis. Both are regulated by feeding/fast-
ing. In particular, SREBP-1c participates in de novo lipogenesis
when dietary carbohydrates are abundant. SREBP-1c tran-
scription is affected by circulating levels of insulin and gluca-
gon, critical hormones in glucose homeostasis, and the oxy-
sterol receptor LXR (Chen et al., 2004). SREBP-2 transcription
is affected by cholesterol availability. Fatty acids can affect
SREBP expression (Xu et al., 2002a; Pawar et al., 2003).
Hepatic fatty acids for activating PPARα and altering SREBP
expression can be derived from several sources. One simple
way to discriminate between sources is by classifying fat as
“new” or “old.” Fatty acids synthesized from carbohydrates
represent new fat. Dietary fatty acids transported to the liver in
chylomicrons represent another source of new fat. New fat
might be retained in the liver (for storage, energy production,
or the synthesis of structural and signaling lipids) or exported
in VLDL to peripheral tissues for metabolism or storage. In the
appropriate milieu, stored or old fat is released from adipose
tissue into the circulation. Those fatty acids not utilized for en-
ergy are returned to the liver where the ultimate fate of this old
fat is poorly understood. Whether new and old fatty acids are
interchangeable or if fatty acids from certain sources are chan-
neled to specific functions is unknown.R INC. DOI 10.1016/j.cmet.2005.04.002 309
A R T I C L ETo test the hypothesis that the metabolic fate of fatty acids
depends on their site of origin, we engineered mice with liver-
specific inactivation of fatty-acid synthase, the enzyme cata-
lyzing the first committed step in fatty-acid biosynthesis (Se-
menkovich, 1997). FAS is a large multifunctional protein with
seven catalytic domains required to convert dietary carbohy-
drates into saturated fatty acids, mostly palmitate (C16:0).
Germline FAS−/− mice die at the preimplantation stage, and
even FAS+/− mice have increased fetal demise, indicating an
absolute requirement for FAS function during embryonic devel-
opment (Chirala et al., 2003). Unlike FAS−/− mice, FASKOL (for
FAS knockout in liver) animals are viable, allowing us to assess
the impact of hepatic de novo lipogenesis on metabolism. Our
results show that new but not old fat activates physiologically
distinct pools of PPARα in liver to affect glucose, fatty-acid,
and cholesterol homeostasis.
Results
Generation of FASKOL mice
ES cells, identified as appropriately targeted by a vector with
loxP sites flanking exons 4–8 of the mouse FAS gene (Figure
1A), were used to generate chimeric mice. Animals carrying the
targeted allele transmitted this locus through the germline to
yield mice heterozygous for the targeted allele (lox+/wt [wild-
type]). Intercrossing lox+/wt mice yielded offspring consistent
with Mendelian inheritance (24% lox+/lox+, 22% wt/wt, and
54% lox+/wt). All three genotypes were indistinguishable in
terms of body weight, body composition, hepatic FAS mRNA,
hepatic FAS enzyme activity, and plasma chemistries (data not
shown), indicating that the loxP sites and NEO cassette did not
interfere with FAS expression.
Mice carrying the “silent” targeted allele were crossed with
animals expressing Cre recombinase driven by the adenovirus
EIIa promoter (EIIaCre). EIIaCre-mediated recombination oc-
curs early in development (2–8 cell stage) and at low levels,
resulting in chimerism with selective deletion of the NEO cas-
sette in some animals. Analysis of DNA from offspring of lox+/
wt × EIIaCre+/− matings documented the presence of all pos-
sible deletion patterns. As expected, intercrossing mice carry-
ing the floxed allele with the NEO cassette deleted yielded
Mendelian proportions of each genotype, normal body and
plasma characteristics, and normal hepatic FAS mRNA as well
as enzyme activity in each genotype (data not shown). The
lox+/wt × EIIaCre cross also produced FAS-deficient alleles
(heterozygotes with deletions of exons 4–8). FAS enzyme activ-
ity was decreased by w50% in tissues of heterozygotes, and
multiple intercrosses using these mice produced no homozy-
gotes, confirming the embryonic lethality of complete FAS defi-
ciency (Chirala et al., 2003).
FASKOL mice, with liver-specific inactivation of the FAS
gene, were produced by crossing lox+/wt mice with rat albumin
promoter-Cre transgenic mice, which express Cre exclusively
in postpartum liver (Postic and Magnuson, 2000). Double hetero-
zygous [lox+/wt Cre+/−] progeny were mated with lox+/wt litter-
mates (lacking the albumin-Cre transgene) to yield FASKOL
mice [lox+/+ Cre+] as well as three different groups of littermate
controls: [lox+/+ Cre−], [lox−/− Cre+], and [lox−/− Cre−]. FASKOL
mice were born at the expected frequency of 12.5%, indicating
that the combination of the floxed allele and the Cre transgene
was not associated with prenatal lethality. Newborn FASKOL310mice were indistinguishable from their control littermates,
nursed successfully, weaned normally, and were active and
fertile.
Rearrangement of the FAS gene was restricted to the liver in
FASKOL mice (Figure 1B). Southern blotting revealed a 7.3 kb
native allele in DNA from control mice (W in Figure 1B) carrying
the Cre transgene without the floxed FAS gene. Only the 8.9
kb floxed allele was detected in nonhepatocyte DNA from
FASKOL (F in Figure 1B) mice. A 5.3 kb fragment, the predicted
size following deletion of exons 4–8, was detected only in
FASKOL (F) liver but not lung, heart, brain, kidney, or skeletal
muscle. It was also absent from liver of mice carrying the
floxed allele without Cre (F− in Figure 1B). A less intense band
at 8.9 kb, representing the floxed allele without rearrangement,
was also present in DNA from FASKOL liver, reflecting nonhe-
patocytes in liver that would not be expected to transactivate
the albumin promoter to express Cre. Liver-specific rearrange-
ment of the FAS gene in FASKOL mice was confirmed by PCR.
A 317 bp product indicating deletion of exons 4–8 was seen
only in liver in the presence of the floxed locus and Cre (Figure
1C, lane 3), not in livers of three different control mice (lanes
2,4,5), and not in other FASKOL tissues such as heart (lane 7).
Liver FAS enzyme activity was decreased by w80% (range
65%–95%) in FASKOL mice as compared to animals from
three different control groups (Figure 1D, upper panel). Maximal
effects were not seen until the age of 16–20 weeks. Since FAS
expression is ubiquitous and hepatocytes comprise 80%–85%
of liver cells, residual liver activity in FASKOL mice is likely due
to nonparenchymal cells. FAS activity was unaffected in lung
(inset, Figure 1D), adipose tissue, heart, and brain of FASKOL
mice.
Since FAS synthesizes palmitate (C16:0) from malonyl-CoA,
inactivation of FAS should increase malonyl-CoA and decrease
palmitate. In overnight-fasted-12 hr chow-refed mice (Figure 1D,
lower panel), malonyl-CoA content was 3-fold higher (14.1 ±
3 nmol/g tissue) in FASKOL liver as compared to animals carry-
ing the floxed allele without Cre (4.5 ± 2.3 nmol/g tissue).
Levels were unaffected in other tissues of FASKOL mice (not
shown). To evaluate metabolism under conditions known to be
associated with induction of FAS activity, mice were fed a high-
carbohydrate diet without fat (zero-fat diet or ZFD). The differ-
ence in hepatic malonyl-CoA persisted under these conditions:
11.0 ± 2.1 nmol/g in FASKOL versus 5.1 ± 1.6 nmol/g in con-
trols. Without a dietary source of palmitate (ZFD), hepatic pal-
mitate content assayed by GC/MS using deuterated palmitic
acid as internal standard was decreased in FASKOL mice (Fig-
ure 1E) as compared to control mice (“wt” or lox+/+ Cre−)
Metabolic characterization of FASKOL mice
Although there were no phenotypic differences among the
three different control mouse groups, all subsequent compari-
sons were made between FASKOL mice and lox+/+ Cre− (wt)
mice. On a normal chow diet, FASKOL mice had lower fasting in-
sulin levels and a lower insulin/glucagon ratio compared to wt
mice, but there were no differences in body weight, adiposity,
metabolic rate, food intake, and several other metabolic
parameters (Table 1). Serum cholesterol was the notable ex-
ception; fasting cholesterol was w40% lower (p < 0.01) in
chow-fed FASKOL mice (see below).
The effects of the ZFD in FASKOL mice were striking. Fasting
glucose decreased 50%–60% in FASKOL mice, insulin levelsCELL METABOLISM : MAY 2005
Hepatic fatty-acid synthase deficiency and PPARαFigure 1. Targeting of the fatty-acid synthase gene
A) Wild-type, targeting vector, and the fatty-acid synthase (FAS) lox allele before and after recombination. The post-Cre allele depicts the deletion of exons 4–8 (gray
shaded boxes). NEO, neomycin positive-selection cassette; open boxes, exons preserved; black arrowheads, loxP sites; open arrowheads, genotyping primers.
B) Southern blot analysis of DNA from control (W, lox−/− Cre+; F−, lox+/+ Cre−) and FASKOL (F, lox+/+ Cre+) mice. Genomic DNA (from liver, lung, heart, brain, kidney,
and skeletal muscle) was digested with NdeI and HindIII and detected using probe C to yield the expected fragments of 7.3 kb (allele without loxP), 8.9 kb (floxed
allele), and 5.3 kb (post-Cre allele).
C) PCR analysis. DNA from FASKOL livers (lox+/+ Cre+) produced a 317 bp product (lane 3) indicating appropriate deletion at the FAS gene. The product was absent
in the livers of wt control mice of various genotypes. It was also absent in hearts of FASKOL mice (lane 7).
D) Assessment of FAS activity (upper panel) and malonyl-CoA content (lower panel). Liver homogenates from overnight-fasted 12 hr chow-refed male FASKOL (black
bar) and littermate control mice of various genotypes aged 16–20 weeks were assayed for FAS enzyme activity and malonyl-CoA content. The inset of (D) represents
FAS activity in lung tissue of FASKOL (black bar) and wt (lox+/+ Cre−, white bar) mice. Each bar represents the mean ± SEM of eight mice of each genotype. *, p < 0.05.
E) Gas chromatography retention peaks of hepatic palmitate (C16:0) and palmitoleate (C16:1) from chow and zero-fat diet (ZFD) fed wt (lox+/+ Cre−) and FASKOL mice. Data
are representative of two independent experiments with four mice per group. The molecular identities of these retention peaks were verified and quantitated by mass
spectrometry. *, p < 0.05.remained low, but glucagon, the key hormonal defense against
hypoglycemia in mammals, increased by w50% (Table 1).
Consistent with stimulation of lipolysis in peripheral tissues by
glucagon, in ZFD-fed FASKOL mice, fat pad weight decreased,
whole-body adiposity decreased, serum NEFA increased, and
liver weight increased in the setting of a modest increase in the
transaminase ALT without affecting other liver function tests
(Table 1). Peripheral fat stores were depleted in ZFD-fed
FASKOL mice, reflected by decreased leptin levels comparedCELL METABOLISM : MAY 2005to ZFD-fed wt mice, and the livers were obviously pale in ZFD-
fed FASKOL mice (not shown), suggesting the presence of he-
patic steatosis.
Reversal of hypoglycemia and fatty liver
in FASKOL mice
ZFD-fed FASKOL mice had distinct, reversible alterations in he-
patic morphology. After 28 days of ZFD, FASKOL mice were hy-
poglycemic (Figure 2A), liver triglyceride content was increased311
A R T I C L ETable 1. Comparisons of wt and FASKOL mice on chow and zero-fat diet
Parameters Chow ZFD
wt FASKOL wt FASKOL
Metabolites and hormones
Glucose (mg/dl) 161 ± 16 145 ± 11 169 ± 13 104 ± 12a,b
NEFA (mEq/l) 0.58 ± 0.04 0.54 ± 0.05 0.48 ± 0.03 0.76 ± 0.1a,b
Insulin (ng/ml) 1.34 ± 0.82 0.63 ± 0.05a 0.94 ± 0.09 0.54 ± 0.14a
Glucagon (pg/ml) 128.3 ± 16.2 134.7 ± 13.1 141.3 ± 12.4 200.0 ± 11.8a,b
Insulin/glucagon ratio 10.4 ± 0.98 4.7 ± 0.18a 6.7 ± 0.21 2.7 ± 0.26a
Leptin (pg/ml) 919.6 ± 162 881.6 ± 132 7712 ± 1149b 1701 ± 330a,b
Adiponectin (ng/ml) 7776 ± 452 7613 ± 312 9012 ± 501 9038 ± 1094
Liver function
ALT (IU/l) 47.0 ± 11 32.0 ± 3.4 32.0 ± 5.3 52.0 ± 13.1a,b
Alk phosphatase (IU/l) 88 ± 1.4 91 ± 2.7 81 ± 1.6 94 ± 1.2
Total Bilirubin (mg/dL) 0.27 ± 0.04 0.31 ± 0.08 0.3 ± 0.06 0.33 ± 0.07
Albumin (g/dl) 2.8 ± 0.1 3.0 ± 0.2 3.1 ± 0.2 3.2 ± 0.14
Energy balance
Body weight (g) 26.5 ± 1.5 26.4 ± 1.2 29.2 ± 2.0 28.4 ± 1.7
Fat content by DEXA (%) 15.5 ± 3.1 13.9 ± 2.0 17.3 ± 3.4 11.4 ± 2.6a
VO2 (ml/g0.75/h) 9.61 ± 1.23 9.2 ± 1.05 10.01 ± 2.04 9.80 ± 1.1
Liver/BW ratio 0.043 ± 0.002 0.039 ± 0.002 0.045 ± 0.003 0.061 ± 0.002a,b
Fat pad/BW ratio 0.026 ± 0.004 0.022 ± 0.004 0.023 ± 0.002 0.013 ± 0.003a,b
Food intake (g/day) 5.35 ± 0.26 5.55 ± 0.05 3.36 ± 0.16b 3.2 ± 0.41b
Male mice (16–20 weeks, n = 6 per group) were either maintained on chow or ZFD for 17 days. Animals were fasted for 4 hr prior to study. Each value represents the
mean ± SEM of six values. p < 0.05 for the following: acompared to corresponding wt mice; bcompared to the corresponding chow-fed mice. BW, body weight. DEXA,
dual-energy x-ray absorptiometry.(Figure 2B), and plasma ALT levels were modestly increased (Fig-
ure 2C). ZFD-induced hypoglycemia and ALT elevation in
FASKOL mice resolved completely after reinstitution of chow
diet for 17 days with values similar to those seen in control
mice fed chow only. However, hepatic triglycerides remained
elevated albeit at significantly lower levels than on ZFD (Figures
2A–2C). Hepatic glycogen stores, determined by PAS staining,
were decreased in ZFD-fed FASKOL mice (Figure 2E, middle
panel) compared to ZFD-fed wt mice (Figure 2D, middle panel)
and replenished after reintroduction of chow (Figure 2E, lower
panel). Hepatic lipid content, determined by oil red O staining
(ORO), mirrored the quantitative hepatic triglyceride determina-
tion—increased in ZFD-fed FASKOL mice (Figure 2E, middle
panel) compared to ZFD-fed wt mice (Figure 2D, middle panel)
and significantly reduced after chow feeding (Figure 2E, lower
panel). As controls, liver sections from chow-only fed wt and
FASKOL mice were also stained with PAS and ORO (Figures
2D and 2E, upper panel), and they showed no difference be-
tween the genotypes.
Hypoglycemia and steatohepatitis are characteristic of PPARα
deficiency. To determine if the metabolic derangements in
ZFD-fed FASKOL mice were related to defective activation of
PPARα-dependent pathways, the potent PPARα activator
Wy14,643 was incorporated into both the chow and zero-fat
diets. A time course of the effects of ZFD on fasting glucose is
shown in Figure S1A. Glucose tended to be lower by 3 days
and plateaued at significantly lower levels between days 10
and 28. Consumption of the Wy compound with ZFD for 10
days significantly increased glucose levels in FASKOL mice
compared to FASKOL mice eating the ZFD alone (Figure 3A).
In contrast, addition of the Wy compound to chow diet for 10
days did not result in a significant change in glucose in either
wt or FASKOL mice compared to chow diet alone (Figure 3A).
ZFD-induced hypoglycemia in FASKOL mice was associated312with lower glucose levels at all time points in intraperitoneal
(i.p.) glucose tolerance tests compared to ZFD-fed wt mice
(Figure S1B, upper panel). Incorporation of the Wy compound
into the ZFD tended to raise glucose levels in FASKOL mice
relative to wt. However, there were no differences in insulin-
tolerance tests between the genotypes with any of the dietary
treatments (Figure S1B, lower panel). Thirty minutes after i.p.
glucose, FASKOL mice showed decreased glucose with insulin
levels similar to wt (Figure S1C). C peptide and insulin ratios
were also similar between the genotypes on both chow and
ZFD (Figure S1D).
The hormonal response to ZFD-induced hypoglycemia in
FASKOL mice was appropriate, with decreased insulin (Figure
3B) and increased glucagon (Figure 3C), yielding a low insulin/
glucagon ratio (Figure 3D) compared to normoglycemic ZFD-
fed wt mice. The Wy compound fed with either chow or ZFD
had no effect on insulin/glucagon ratios, although absolute in-
sulin and glucagon levels were reduced in ZFD+Wy-fed wt and
FASKOL mice (Figures 3B–3C).
Hepatic glycogen depletion and triglyceride accumulation in
ZFD-fed FASKOL mice were also prevented by the Wy com-
pound. Lower glycogen content in ZFD-fed FASKOL mice (8.6 ±
1.8 mol/g) compared to ZFD-fed wt mice (17.8 ± 4.1 mol/g)
did not occur in ZFD+Wy-fed FASKOL mice nor in chow+
Wy-treated wt and FASKOL mice (Figure 3E). ZFD-fed FASKOL
liver triglyceride content (14.1 ± 0.33 mg/g) was nearly twice
that of ZFD-fed wt livers (8.3 ± 0.28 mg/g) but not in the pres-
ence of dietary Wy compound (Figure 3F). No further reduction
in hepatic triglyceride content was noted in either wt or
FASKOL mice treated with chow+Wy, compared to chow feed-
ing alone. This quantitative analysis was confirmed histologi-
cally, as shown in Figures 3K and 3L. The marked steatosis
noted in ZFD-fed FASKOL mice (Figure 3L, 2nd panel) did not
occur in the presence of Wy compound (Figure 3L, 4th panel).CELL METABOLISM : MAY 2005
Hepatic fatty-acid synthase deficiency and PPARαFigure 2. Zero-fat diet induces relative hypoglycemia with glycogen depletion and steatohepatitis that is reversed with chow feeding
A–C) Four hour fasting serum glucose (A), liver triglyceride (B), and alanine aminotransferase (C) concentrations in 16- to 20-week-old male wt (lox+/+ Cre−, white bars)
and FASKOL (black bars) mice fed ZFD for 28 days (ZFD28d) and then switched to chow (ZFD28d/chow), or maintained only on chow for the duration of the study
(Chow). Each bar represents the mean ± SEM of 4–5 mice of each genotype per group. p < 0.05 for the following: *, compared to the corresponding wt mice; #,
compared to the corresponding chow-fed mice; **, compared to the corresponding 28 day ZFD-fed mice.
D and E) Liver histology for wt (lox+/+ Cre−) and FASKOL mice. After 28 days of ZFD feeding (middle panel), subgroups of the 16- to 20-week-old wt and FASKOL
mice were switched to chow diet for 17 days (lower panel). As controls, four mice from each genotype were maintained only on chow diet for the duration of the study
(upper panel). Sections from chow-only fed (chow), ZFD-fed (ZFD28d), and chow-switched (ZFD28d/chow) animals were stained with periodic acid schiff (PAS) or oil
red O (ORO), magnification 10×. Vacuolation seen in 28 day ZFD-fed FASKOL mice (arrows) was mostly lipid as shown by ORO staining. Sections are representative
of several animals for each condition.Serum triglyceride and NEFA levels (Figures 3G and 3H) in both
wt and FASKOL mice were markedly decreased upon ingestion
of Wy in both chow and ZFD, as expected.
FASKOL mice on a chow diet had low levels of serum and
hepatic cholesterol that were unaffected by ZFD feeding (Fig-
ures 3I and 3J). Both were increased in FASKOL mice when
PPARα was activated using Wy14,643 in both the chow and
ZFD (Figures 3I and 3J). In contrast, there were no significant
effects on cholesterol levels in wt mice fed chow+Wy (Figures
3I and 3J).
The reversal of hypoglycemia and hypocholesterolemia after
ZFD+Wy feeding in FASKOL mice suggested that activation of
PPARα-dependent pathways was involved. To determine if
PPARα deficiency contributed to the phenotype, whole-body
PPARα knockout (PPARα−/−) mice were subjected to the same
dietary challenge described above. Despite having a lower fasting
glucose on chow, PPARα−/− mice did not manifest any further
decrease in glucose levels after 10 days of ZFD feeding (FigureCELL METABOLISM : MAY 2005S2A). Glucose levels were unaffected by Wy feeding with either
chow or ZFD. In contrast, C57BL/6 littermate control mice had
significantly higher glucose on chow that decreased after
ZFD+Wy feeding (Figure S2A). Similarly, cholesterol levels were
unaffected in PPARα−/− mice regardless of diet and remained
significantly higher than C57BL/6 control mice with both chow
and ZFD feeding (Figure S2B). Consistent with previous reports
(Xu et al., 2002b), fasting insulin levels in PPARα−/− mice
tended to be higher than in the C57BL/6 control mice under all
dietary conditions (not shown). Also as expected in the
PPARα−/− mice, NEFA levels were higher than in control mice,
with no decrease in either NEFA or triglyceride levels after Wy
feeding, in contrast to control mice (Figures S2C and S2D).
PPAR activation and the expression of glucose
metabolism genes
To address the mechanisms by which ZFD-fed FASKOL mice
manifest hypoglycemia and their subsequent restoration to313
A R T I C L EFigure 3. Effects of PPARα activation on glucose and lipid homeostasis in FASKOL and wt (lox+/+ Cre−) mice
A–J) Measurements of serum glucose (A), insulin (B), glucagon (C), insulin to glucagon ratio (D), liver glycogen (E), liver triglycerides (F), serum triglycerides (G), serum
nonesterified fatty acids (H), serum total cholesterol (I), and liver cholesterol content (J) were obtained from 4 hr fasted wt and FASKOL mice on chow or zero-fat diet
for 10 days (ZFD), or PPARα agonist Wy14,643 added to chow (C+Wy) or ZFD (Z+Wy) for 10 days. Each bar represents the mean ± SEM values of 6–8 male wt and
FASKOL mice, aged 16–20 weeks, fed the various diets. p < 0.05 for the following: *, compared to the corresponding wt mice; #, compared to the corresponding
chow-fed mice; **, compared to the corresponding ZFD-fed mice. White bars, wt; black bars, FASKOL.
K and L) Liver histology for chow (panel 1), ZFD for 10 days (panel 2), chow+Wy14,643 for 10 days (panel 3), and ZFD+Wy14,643 for 10 days (panel 4) fed wt and
FASKOL mice. Liver sections from the above animals were stained with hematoxylin and eosin (H&E) and oil red O (ORO), magnification 10×. The prominent vacuolation
seen in ZFD-fed FASKOL mice (arrows, panel 2) stained positive for ORO (panel 2). Sections are representative of several animals for each condition.normoglycemia with PPARα activation, we studied the expres-
sion of PPARα target genes critical for gluconeogenesis (Figure
4). Messenger RNA levels for PPARα itself were unaffected in
FASKOL mice on chow and ZFD in liver (Figure 4A), as well as
in kidney and heart, two other tissues known to have high
PPARα expression (Figure S3A). PPARα mRNA levels were ap-
propriately induced after both chow+Wy and ZFD+Wy feeding
in all tissues analyzed (Figure 4A and Figure S3A) since PPARα
activation is known to stimulate its own transcription.314Induction of gluconeogenic genes is regulated in part
through PGC-1α, via PPARα-dependent induction of TRB3
(Koo et al., 2004). Expression of these genes was markedly
changed in ZFD-fed FASKOL livers and responded to PPARα
activation. PGC-1α expression was increased in ZFD-FASKOL
livers (Figure 4A), likely due to elevated glucagon (Figure 3C),
and appropriately stimulated by Wy in both genotypes on ZFD,
but only in the FASKOL mice on chow+Wy (Figure 4A). Expres-
sion of TRB3, a recently identified PPARα target (Koo et al.,CELL METABOLISM : MAY 2005
Hepatic fatty-acid synthase deficiency and PPARαFigure 4. Expression of PPARα target genes and proteins involved in gluconeogenesis
A and B) Quantitative RT-PCR of RNA isolated from the livers of 4 hr fasted 16- to 20-week-old male wt (lox+/+ Cre−, white bars) and FASKOL (black bars) mice
maintained on chow, ZFD for 10 days (ZFD), chow+Wy14,643 for 10 days (C+Wy), and ZFD+Wy14,643 for 10 days (Z+Wy). Data are mean ± SEM of three independent
RT-PCR experiments for each gene with four mice of each genotype per dietary treatment for each experiment. Data are presented relative to L32 ribosomal mRNA in
the same samples and the relative mRNA levels were determined by QPCR using the comparative CT method. p < 0.05 for the following: *, compared to the
corresponding wt; #, compared to the corresponding chow-fed mice; **, compared to the corresponding ZFD-fed mice.
C and D) Immunoblot analysis of hepatic Akt (C) and GSK3β (D) from wt (W) and FASKOL (F) mice on the various diets as described in (A)–(B) above. Upper panels
of (C) and (D) represent Akt phosphorylation on 473Ser (αP-Akt) and GSK3β phosphorylation on 9Ser (αP-GSK3β), respectively. Middle panels represent the total Akt
and GSK3β proteins detected after stripping and reprobing the membranes with pan-Akt (α-Akt) and GSK3β (α-GSK3β) antibodies, respectively. The gels were scanned
and quantified by densitometry. Intensities of the phosphorylated and total protein bands of wt mice on chow diet (control, lane 1) was arbitrarily set at 100%, and the
relative intensities of the other bands were expressed relative to the control. Each bar represents mean ± SEM for 3–4 male wt and FASKOL mice. p < 0.05 for the
following: *, compared to the corresponding wt; #, compared to the corresponding chow-fed mice; **, compared to the corresponding ZFD-fed mice.2004), and HNF4α, another transcription factor coactivated by
PGC-1α (Rhee et al., 2003), were both suppressed in ZFD-fed
FASKOL livers and were significantly induced by PPARα acti-
vation with Wy in both the chow and ZFD in FASKOL livers
(Figure 4A). Recent data from Yamamoto et al. (2004) imply that
HNF4α expression is regulated by the insulin/glucagon ratio as
well, through crosstalk with SREBP-1c and its interference with
PGC-1α recruitment. HNF4α was shown to be absolutely re-
quired to induce gluconeogenic genes, as liver-specific HNF4α
knockout mice had impaired induction of glucose 6-phos-
phatase (G6Pase) and phosphoenolpyruvate carboxykinase
(PEPCK) even when PGC-1α was maximally activated (Rhee et
al., 2003). Our results are consistent with these reports, with
decreased expression of the gluconeogenic genes G6Pase, pyru-
vate carboxylase (PC), and PEPCK in ZFD-fed FASKOL livers
(Figure 4B).CELL METABOLISM : MAY 2005Carbohydrate feeding is known to increase gluconeogenic
flux (Bizeau et al., 2001), explaining the increase in G6Pase,
PC, and PEPCK expression with the ZFD in wt mice. The failure
of this response, in concert with suppressed hepatic HNF4α
despite a 3-fold induction of PGC-1α, provides a mechanism
for the low glucose (Table 1; Figures 2A and 3A) in ZFD-fed
FASKOL mice. Activation of PPARα with Wy in both chow and
ZFD resulted in significant induction of G6Pase and PC above
their respective baseline levels, but PEPCK was unaffected by
Wy feeding (Figure 4B). This is consistent with previous re-
ports, showing that PEPCK is not a PPARα target in liver (Ker-
sten et al., 1999). Expression of FOXO1, another transcription
factor required for PGC-1α-mediated induction of gluconeoge-
nic genes (Puigserver et al., 2003), was also decreased in ZFD-
fed FASKOL mice but did not increase with Wy compound
(not shown).315
A R T I C L EExpression of glucokinase (GK) showed an appropriate ex-
pression pattern (Figure 4B) consistent with the low-insulin/
high-glucagon hormonal milieu of the hypoglycemic ZFD-
fed FASKOL mice. Carbohydrate feeding induces GK (Com-
merford et al., 2002). This response was attenuated in ZFD-fed
FASKOL mice since GK mRNA levels were identical to those
of chow-fed mice (Figure 4B). Incorporation of Wy in either
chow or ZFD decreased GK expression in FASKOL but not wt
liver (Figure 4B).
To further define the mechanisms underlying ZFD-induced
hypoglycemia in FASKOL mice, Akt/PKB and glycogen syn-
thase kinase 3-β (GSK3β), regulators of glucose and glycogen
metabolism respectively, were analyzed in wt and FASKOL
mice. There were no effects in skeletal muscle (not shown).
ZFD feeding in FASKOL mice increased hepatic 473serine-
phosphorylated Akt (Figure 4C, lane 4) and 9serine-phosphory-
lated GSK3β (Figure 4D, lane 4) compared to chow (lane 2,
Figures 4C and 4D). Addition of Wy to chow and ZFD resulted
in a marked decrease in the phosphorylated forms of Akt and
GSK3β to levels similar to those seen with chow-only feeding
(compare lanes 6 and 8 to lane 2, Figures 4C and 4D). These
data suggest that enhanced hepatic insulin signaling in ZFD-
fed FASKOL mice leads to decreased expression of gluco-
neogenic genes, ultimately causing hypoglycemia.
PPAR activation and the expression of fatty-acid and
cholesterol metabolism genes
Similar to the striking changes in glucose-regulating genes,
PPARα target genes critical for fatty-acid metabolism were de-
creased in ZFD-fed FASKOL livers (Figure 5A) and restored by
pharmacological activation of PPARα. Expression of acyl-CoA
oxidase (ACO), a peroxisomal fatty-acid oxidation enzyme and
known PPARα target gene, was reduced by w50% in the livers
of ZFD-fed FASKOL mice (Figure 5A) but was unaffected in
kidney and heart (Figure S3B). As expected, ACO expression
was increased to the same level as wt in liver (Figure 5A) as
well as in kidney and heart (Figure S3B) when the Wy com-
pound was combined with either the chow or ZFD. PPARα pro-
motes ketone production. Expression of the mitochondrial en-
zyme HMG-CoA synthase-2 (HS-2), rate-limiting for hepatic
ketogenesis and another known PPARα target gene, was de-
creased in ZFD-fed FASKOL mice and induced to the same
level as wt when Wy was combined with ZFD but was almost
3-fold higher than wt with chow+Wy feeding (Figure 5A). The
expression of liver fatty-acid binding protein (L-FABP), a
PPARα target shown to physically interact with PPARα (Wolf-
rum et al., 2001), was reduced in ZFD-fed FASKOL livers, while
it was increased in ZFD-fed wt livers compared to chow diet
(Figure 5A). As expected for a PPARα target gene, it was in-
duced with Wy feeding.
SREBP-1c expression was decreased in chow- and ZFD-fed
FASKOL mice and was unaffected by Wy treatment compared
to wt mice, consistent with the persistently low insulin levels in
FASKOL mice (Figure 3B). SREBP-1c mRNA levels were unaf-
fected by chow+Wy treatment but modestly decreased with
ZFD+Wy feeding compared to ZFD alone (Figure 5A), likely re-
flecting the lower insulin in wt and FASKOL mice under these
conditions (Figure 3B).
Lipoprotein lipase (LPL), a gene not normally expressed at
high levels in adult liver but known to be induced by glucagon
(Julve et al., 1996), was decreased in chow-fed FASKOL livers.316It was induced >40-fold with ZFD feeding in FASKOL mice (Fig-
ure 5A), which have high glucagon levels (Figure 3C). LPL is
also known to be increased by PPARα ligands (Li et al., 2002),
and its expression was induced 7- to 10-fold with chow+Wy
feeding and 40- to 45-fold with ZFD+Wy feeding in both wt
and FASKOL mice (Figure 5A). In contrast, carnitine palmi-
toyltransferase-1a (CPT-1a) was not affected in FASKOL livers
under different feeding and ligand-treatment conditions (Fig-
ure 5A).
FASKOL mice had low levels of serum and hepatic choles-
terol that were unaffected by the absence of dietary fat, and
these levels were increased by PPARα activation (Figures 3I
and 3J). To determine if decreased hepatic cholesterol content
in this model was due to decreased cholesterol synthesis, in-
creased excretion, or some combination of both, we analyzed
the message levels for proteins mediating these processes.
SREBP-2 expression was increased in FASKOL liver (Figure
5B), the expected response to diminished intracellular choles-
terol levels (Sato et al., 1996). SREBP-2 is induced when the
intracellular sterol content is low, stimulating the expression of
genes required for cholesterol synthesis. Despite the appropri-
ate induction of SREBP-2, the expression of HMG-CoA reduc-
tase, a major SREBP-2 target gene and the rate-limiting enzyme
in cholesterol synthesis, was decreased in both chow- and ZFD-
fed FASKOL mice (Figure 5B). The expression of insulin-induced
gene 1 (Insig-1), which has been shown to inhibit cholesterol
synthesis by blocking the proteolytic processing of SREBPs
(Yang et al., 2002) and inducing proteosomal degradation of
HMG-CoA reductase (Sever et al., 2003), was increased in
chow- and ZFD-fed FASKOL livers compared to wt (Figure 5B).
Hepatic cholesterol synthesis, determined in vivo using tritiated
water, was reduced by more than 50% in both chow- and ZFD-
fed FASKOL mice (Figure 5C). Treatment with the PPARα acti-
vator increased hepatic cholesterol biosynthesis by w2.5-fold,
markedly reduced Insig-1 expression (Figure 5B), increased
HMG-CoA reductase expression (Figure 5B), increased hepatic
cholesterol content (Figure 3J), and appropriately decreased
SREBP-2 expression (Figure 5B) in FASKOL mice.
The nuclear receptor LXRα and its target genes ABCG5 and
ABCG8 are important regulators of cholesterol efflux (Repa et
al., 2002). Steady-state levels of mRNA for LXRα, ABCG5, and
ABCG8 (Figure 5B), as well as ABCA1 (not shown) were unaf-
fected in FASKOL mice and did not change with diet or Wy
treatment. The mRNA levels of two apoproteins, apoB and
apoE, involved in cholesterol export were also unaffected (not
shown). Collectively, these data suggest that disruption of FAS,
regardless of dietary fat content, decreased hepatic cholesterol
content by impairing cholesterol synthesis.
Prolonged fasting In FASKOL mice causes hypoglycemia,
hepatic lipid accumulation, and decreased expression
of PPAR target genes that are prevented
by PPAR activation
To confirm the observation that hepatic deficiency of FAS in-
terferes with PPARα activation, we used a different model than
ZFD feeding. Mice were subjected to a 24 hr fast (Figure S4).
FASKOL mice became hypoglycemic (Figure S4A), had de-
creased serum levels of the ketone β-HBA (Figure S4B), and
had elevated circulating NEFA (Figure S4C), effects that were
reversed by i.p. administration of the PPARα activator at the
initiation of the fast. Increased liver triglyceride content in 24CELL METABOLISM : MAY 2005
Hepatic fatty-acid synthase deficiency and PPARαFigure 5. Expression of genes involved in lipid metabolism and measurement of in vivo liver cholesterol synthesis
A and B) Quantitative RT-PCR of RNA from livers of wt (lox+/+ Cre−, white bars) and FASKOL (black bars) mice fed chow, ZFD for 10 days (ZFD), chow+Wy14,643 for
10 days (C+Wy), and ZFD+Wy14,643 for 10 days (Z+Wy). Data are mean ± SEM of three independent RT-PCR experiments for each gene with four mice of each
genotype per dietary treatment for each experiment. Data are presented relative to L32 ribosomal mRNA in the same samples and the relative mRNA levels were
determined by QPCR using the comparative CT method. p < 0.05 for the following: *, compared to the corresponding wt; #, compared to the corresponding chow-fed
mice; **, compared to the corresponding ZFD-fed mice.
C) Hepatic cholesterol synthesis rates were determined in wt (white bars) and FASKOL (black bars) mice fed the various diets as described in (A) and (B) above using
3H-water. Incorporation of 3H-radioactivity into digitonin-precipitable sterols (DPS) was expressed as moles per hour per gram of tissue. Each bar represents the
mean ± SEM of 3–5 male mice per genotype per dietary treatment. p < 0.05 for the following: *, compared to the corresponding wt; #, compared to the corresponding
chow-fed mice; **, compared to the corresponding ZFD-fed mice.hr fasted FASKOL mice was also prevented by Wy compound
(Figure S4D).
Gene expression in FASKOL mice subjected to the pro-
longed fast mirrored that of ZFD-fed animals. Although PPARα,
PGC-1α, and TRB3 message levels were unaffected by geno-
type after a 24 hr fast, only the latter two genes were preferen-CELL METABOLISM : MAY 2005tially induced by Wy injection in the FASKOL mice, while
PPARα expression was increased by Wy in both wt and
FASKOL mice (Figure S4E). The expression of HNF4α in
FASKOL livers after a 24 hr fast was similar to that seen in
ZFD-fed FASKOL livers and was significantly induced by Wy
(Figure S4E). The mRNA levels of cAMP response element317
A R T I C L Ebinding protein (CREB), regulated in the fasting state by gluca-
gon, were higher in 24 hr fasted FASKOL mice with and without
Wy injection, compared to wt (Figure S4E). CPT-1a was lower
in 24 hr fasted FASKOL livers (Figure S4F), different from the
response in ZFD-fed FASKOL mice (Figure 5A), and unaffected
by Wy administration. Expression of ACO, HS-2, PC, and
G6Pase (Figure S4F), PPARα target genes involved in fatty-acid
oxidation, ketogenesis, and gluconeogenesis, was decreased
after a 24 hr fast in FASKOL mice, mirroring the expression
patterns seen in ZFD-fed FASKOL mice, and all were induced
to wt levels when the PPARα activator was injected at the initi-
ation of the fast (Figure S4F).
Discussion
A model for differential effects of new versus
old fat in liver
Fatty acids can serve as signaling molecules (Pegorier et al.,
2004), especially in the liver, where perturbations of normal nu-
trient homeostasis in conditions such as insulin resistance, dia-
betes, and obesity result in the accelerated production of glu-
cose and atherogenic lipoproteins, common contributors to
human disease. In this paper, we show that the source of these
fatty acids is critical for maintaining normal glucose, lipid, and
cholesterol metabolism.
When FASKOL mice (lacking the capacity to synthesize fatty
acids from carbohydrate) were fed a diet without fat, they de-
veloped hypoglycemia and fatty liver in the setting of de-
creased expression of PPARα target genes (Table 1; Figures
2–5). The same effects were seen when FASKOL mice were
subjected to prolonged fasting (Figure S4), as in PPARα-defi-
cient mice. Malonyl-CoA participates in the regulation of fatty-
acid oxidation but is unlikely to mediate the FASKOL pheno-
type since differences in malonyl-CoA were unaffected by diet
(Results). The hypoglycemia/steatohepatitis phenotype and
defects in PPARα target gene expression were corrected by ad-
ministration of a potent PPARα agonist (Figures 3–5 and Figure
S4). FASKOL mice also had a cholesterol phenotype that, un-
like the development of hypoglycemia/steatohepatitis, was not
dependent on diet. Regardless of the availability of dietary fat,
serum and hepatic cholesterol levels were low in FASKOL mice
in association with increased SREBP-2, decreased HMG-CoA
reductase gene expression, and decreased hepatic cholesterol
synthesis (Figures 3 and 5). These effects were also normalized
by pharmacologically activating PPARα (Figures 3 and 5). Thus,
the metabolic abnormalities in FASKOL mice appear to be
driven by the failure to activate available PPARα. PPARα−/−
mice did not develop a phenotype with ZFD feeding (Figure S2).
Our results are consistent with the model shown in Figure 6
indicating that new fatty acids are the endogenous activators
of physiologically distinct pools of PPARα. FASKOL mice are
protected from the hypoglycemia/steatohepatitis phenotype
when new fat absorbed from the diet (D in Figure 6) is available
to activate one pool of PPARα and promote gluconeogenesis
(GNEO) as well as fatty-acid oxidation (FAO). Regardless of
diet, FASKOL mice have low hepatic stores of cholesterol that
are normalized by PPARα activation, suggesting that new fat
produced by FAS (N in Figure 6) has access to a separate pool
of PPARα capable of stimulating cholesterol biosynthesis
(CHOL) in addition to gluconeogenesis and fatty-acid oxida-
tion. New fat synthesized by FAS may be the preferred endoge-318nous PPARα activator. Even in the presence of dietary fat,
FASKOL mice tend to have lower glucose levels, insulin levels
are significantly lower (Table 1), and mRNA levels for the gluco-
neogenic enzymes G6Pase and PC (Figure 4B) are significantly
induced, suggesting the need for increased gluconeogenesis
(perhaps driven by dietary fat) in the absence of FAS. Over
time, ZFD-fed FASKOL mice mobilize peripheral fat stores and
transport this lipid to the liver where it accumulates (old fat in
Figure 6). But this lipid source fails to activate PPARα, blood
glucose and cholesterol levels remain low, and steatohepatitis
progresses. Thus, specific fatty-acid pools synthesized by he-
patic FAS or derived from the diet, but not those stored in the
liver after transfer from the periphery (even when present in
abundance), activate PPARα to impact glucose and lipid me-
tabolism. While these observations establish the existence of
distinct physiological lipid compartments, identification of the
precise subcellular location of these compartments will require
additional studies.
FASKOL mice and the disruption
of cholesterol metabolism
Impaired activation of PPARα is a feasible cause of the hypo-
glycemia/fatty-liver phenotype in our mice since this ligand-
activated transcription factor is known to play important roles
in gluconeogenesis (Bernal-Mizrachi et al., 2003; Koo et al.,
2004), fatty-acid oxidation (Reddy, 2001), and ketogenesis (Rod-
riguez et al., 1994). FASKOL mice also had abnormal choles-
terol metabolism, characterized by decreased activation of a
critical SREBP-2 target gene (HMG-CoA reductase), that was
corrected by treatment with a PPARα agonist. There is prece-
dence for the involvement of PPARα and peroxisomes in cho-
lesterol metabolism. Peroxisome-deficient PEX2 null mice have
a complex cholesterol phenotype (Kovacs et al., 2004). Hepatic
cholesterol content is decreased, SREBP-2 mRNA is in-
creased, SREBP-1c is decreased, and LXR target genes are
not activated, effects also seen in FASKOL mice. In whole-
body PPARα null mice, hepatic cholesterol and HMG-CoA re-
ductase expression are decreased (Patel et al., 2001). PPARα
activators have been reported to increase HMG-CoA reductase
gene expression in hepatocytes (Le Jossic-Corcos et al.,
2004). Viewed together, these data suggest that normal peroxi-
somal function is required to maintain cholesterol homeostasis.
Cholesterol metabolism in FASKOL mice shares some fea-
tures with transgenic mice overexpressing Insig-1 in liver (En-
gelking et al., 2004) and liver-specific HNF4α knockout mice
(Hayhurst et al., 2001). Insigs are ER proteins that, in the pres-
ence of sterols, bind to HMG-CoA reductase and SCAP, an
escort protein required for the generation of transcription-
ally active SREBPs. Insig-1 liver transgenics have decreased
plasma and hepatic cholesterol, decreased activation of
SREBP-2 target genes such as HMG-CoA reductase, and no
effect on LXR or its target genes, resembling FASKOL mice.
Liver-specific HNF4α knockout mice have decreased plasma
cholesterol, fatty liver, decreased expression of PPARα as well
as L-FABP, and normal LXRα expression, as in FASKOL mice.
These data suggest that PPARα signaling through products of
the FAS reaction facilitates SREBP processing and HNF4α ac-
tivation.CELL METABOLISM : MAY 2005
Hepatic fatty-acid synthase deficiency and PPARαFigure 6. Model for differential effects of hepatic
lipid
Fat absorbed from the diet or synthesized de novo
via FAS in the liver constitutes “new” fat, capable of
activating PPARα to ensure normal glucose and
lipid homeostasis. Fat derived from peripheral mobi-
lization of adipose stores constitutes a different he-
patic compartment (“old” fat) that does not appear
to activate PPARα as effectively as new fat, leading
to fatty liver. In contrast to de novo synthesized fat,
dietary fat is inadequate for the maintenance of cho-
lesterol homeostasis, suggesting different PPARα
pools.Is FAS-derived palmitate the endogenous
activator of PPAR?
Our results provide evidence that hepatic FAS is necessary for
the normal activation of PPARα target genes but do not provide
definitive identification of the responsible ligand. The saturated
fatty acid palmitate (16:0) is the major product of the FAS reac-
tion, and palmitate levels were decreased in FASKOL liver (Fig-
ure 1). Although unsaturated fatty acids are generally consid-
ered to be the endogenous ligands for PPARs, several lines of
evidence suggest that palmitate or related FAS products acti-
vate PPARα. Palmitate as well as laurate (12:0) and stearate
(18:0) have been shown to transactivate PPARα using reporter
gene constructs (Kliewer et al., 1997; Gottlicher et al., 1992).
Palmitate, myristate (14:0), and stearate each bind to PPARα
with an affinity similar to that of some unsaturated fatty acids
(Xu et al., 1999). Physiologically, saturated fatty acids stimulate
both gluconeogenesis (Bizeau et al., 2001) and cholesterol syn-
thesis (Glatz and Katan, 1993), processes associated with
PPARα activation. HNF4α shows constitutive binding of satu-
rated as well as unsaturated C14-C18 fatty acids (Wisely et al.,
2002). It is thus plausible that FAS products could affect gene
expression by binding and activating PPARα.
How is new fat compartmentalized
to activate PPAR?
The observation that new fat has specific metabolic effects
implies the existence of discrete physiological compartments.
FAS is a cytosolic enzyme and PPARα, when it activates gene
expression, is in the nucleus. How is the product of a cytosolic
enzyme delivered to a nuclear factor? How does the cell dis-
tinguish between newly absorbed and stored fat? One possi-
bility is that lipid binding proteins specific for new fat shuttle
fatty acids to nuclear PPARα. Liver fatty-acid binding protein
(L-FABP) is present in both cytosol and nucleus and interacts
with PPARα (Wolfrum et al., 2001). However, PPARα target
gene expression is largely preserved in L-FABP null mice
(Newberry et al., 2003; Erol et al., 2004). Another possibility is
that PPARα shuttles between the nucleus and the cytoplasm
with the assistance of chaperones that promote an interaction
with the new fat pool. In support of this notion, cytosolic
PPARα was recently shown to be stably associated with the
chaperone protein hsp90 (Sumanasekera et al., 2003a; Suma-
nasekera et al., 2003b).CELL METABOLISM : MAY 2005In short, all fatty acids are not created equal, at least in the
hepatocyte. De novo lipogenesis mediated by FAS plays a reg-
ulatory role in glucose, lipid, and cholesterol metabolism by
providing an endogenous ligand for activation of PPARα. De-
fining the process by which new fat is preferentially delivered
to PPARα could have important implications for understanding
how nuclear receptor family members that serve as nutrient
sensors distinguish between different sources of fatty acids.
Experimental procedures
Animals
A 9.3 kb HindIII fragment including exons 1–9 of the mouse FAS gene was
isolated from a mouse BAC clone (129/SvJ). A combination of conventional
cloning and long-distance PCR was used to generate the targeting vector
shown in Figure 1A. RW-4 embryonic stem cells were electroporated at the
Washington University ES Core, and 5 of 191 screened colonies were found
to be correctly targeted. One clone (C12) was injected into C57BL/6 blasto-
cysts to generate chimeric mice. Floxed, germline offspring were crossed
with albumin-Cre mice (Postic and Magnuson, 2000) or EIIaCre mice (Lakso
et al., 1996). The Washington University Animal Care Committee approved
these experiments.
Mice were genotyped by PCR using FAS-specific primers (5#-ATGTCTGG
TTGTTCTTGGGCTGA-3# and 5#-GGTCATCGAGACAACCACACAT-3#) and
Cre-specific primers (5#-GCGGTCTGGCAGTAAAAACTATC-3# and 5#-GTG
AAACAGCATTGCTGTCACTT-3#). For Southern blotting, genomic DNA was
isolated using DNAEasy Kit (Invitrogen), digested with NdeI and HindIII, and
detected using Probe C in Figure 1A.
All experiments were performed at 16–20 weeks of age to allow for maxi-
mal effects of albumin-Cre. Animals were fed a standard mouse chow diet
(Purina 5053) with a total fat content of 4.5%, protein content of 22%, and
45%–55% nitrogen-free excess (which includes carbohydrates) by weight,
yielding a total caloric value of w3.0 kcal/g. The zero-fat diet (ZFD) (Harlan
Teklad, TD 03314) consisted of 0% fat, 20% protein, and 63% carbohy-
drates by weight, yielding a total caloric value of 3.3 kcal/g (24% protein/
76% carbohydrate by caloric content). This diet is well tolerated in rodents
(Iritani et al., 2000). In some experiments, animals were fed either chow
or ZFD containing the PPARα agonist Wy14,643 (TD 03579). For this diet,
Wy14,643 (Biomol Research Laboratories) was shipped directly to the sup-
plier and incorporated into standard rodent chow P5053 (Chow+Wy) or TD
03314 (ZFD+Wy) both at 0.1% (wt/wt). Experimental animals were weighed
weekly. Food intake was determined in individually housed mice by weigh-
ing remaining diet and accounting for spillage using metabolic cages. For
24 hr fasting studies, food was withdrawn at the beginning of the light cycle,
and mice were injected intraperitoneally with Wy14,643 (50 g/g in 30%
DMSO) or vehicle alone (30% DMSO) as described (Pedraza et al., 2000).319
A R T I C L EAnalytical procedures
Triglycerides, cholesterol, glucose, nonesterifed fatty acids (NEFA), and in-
sulin were assayed as described (Marshall et al., 1999; Li et al., 2000). Lep-
tin and adiponectin were assayed by ELISA using commercial reagents
(CrystalChem, R&D Systems). Glucagon and C peptide radioimmunoassays
as well as determinations of ALT (alanine aminotransferase), bilirubin, alka-
line phosphatase, albumin, lactate, and β-hydroxybutyrate were performed
in mouse core facilities at Washington University. Body composition and
indirect calorimetry were performed as described (Bernal-Mizrachi et al.,
2002). Glucose-tolerance and insulin-tolerance tests were performed as de-
scribed (Li et al., 2000).
FAS enzyme activity and malonyl-CoA content
FAS enzyme activity was determined using a modification of a previously
described assay (Ullman and White, 1981). Freshly harvested tissues were
weighed and homogenized in 0.1 M potassium phosphate buffer (pH 7.0),
containing 8% sucrose, 1 mM EDTA (pH 8.0), and 20 mM 2-mercapto-
ethanol at 4°C. Homogenates were centrifuged at 3,000 × g for 10 min at
4°C. Ten microliters of the supernatant was added to 80 l of assay buffer
(2 mM EDTA [pH 8.0], 2 mM DTT, 0.4 mg/ml NADPH), and the rate of
NADPH oxidation was monitored at 340 nm. The substrate-dependent rate
was determined by subtracting the NADPH oxidation rate from the rate after
adding 10 l of 0.85 mg/ml of malonyl-CoA (Sigma).
Malonyl-CoA was determined in extracts homogenized in deionized
water. CoA esters were separated using reversed-phase HPLC on a 5 m
Supelco C18 column with a Waters HPLC system, monitoring 254 nm as
the maximal absorbance for CoA. Buffers, gradients, and flow rates were
those described previously (Pizer et al., 2000).
Gas chromatography-mass spectrometry (GC-MS)
Samples were analyzed as described (Turk et al., 1986; Wolf et al., 1991).
Fifty milligram aliquots of frozen liver were homogenized in 3 ml of 2:1 (v/v)
chloroform:methanol and the organic phase isolated. Thirty microliters of
each extract was saponified in 1.0 ml of 5 mM KOH in ethanol for 2 hr at
100°C followed by treatment with 100 l 1.2 N HCl and 2.5 ml of ethyl
acetate. The organic phase was derivatized to methyl esters by the addition
of 100 l HCl:methanol (1:3 v/v) and heating at 70°C for 1 hr. The derivatized
samples were reconstituted in hexane and analyzed on a Varian 3400 gas
chromatograph interfaced to a Finnegan SSQ 7000 mass spectrometer.
Samples were analyzed at injector and transfer line temperatures of 250°C
and ionization was achieved by electron impact. Selected ion monitoring
was used at mass-to-charge ratio (m/z) of 270 and 274 for the methyl esters
of native palmitate and of the 5,5,6,6-palmitic acid-d4 internal standard,
respectively. The ratio of the ion current at m/z 270 and 274 was used to
determine the amount of palmitate by interpolation from a standard curve.
Hepatic assays and histology
Frozen aliquots (25–30 mg) of liver were homogenized in chloroform:metha-
nol (2:1 vol/vol) and extracts analyzed using ThermoDMA triglyceride and
cholesterol reagents (Thermoelectron Corp.). Perchloric acid extracts of
liver were assayed for glycogen by the amyloglucosidase method (Passon-
neau and Lauderdale, 1974). For histology, some livers were fixed in 10%
neutral buffered formalin and embedded in paraffin, and 4–6 m sections
were cut and stained with hematoxylin and eosin (H&E). Other livers were
fixed in alcoholic formalin or frozen in Tissue-Tek OCT (Miles, Inc.) for deter-
mination of glycogen and neutral lipids by periodic acid-schiff (PAS) and
ORO staining, respectively.
In vivo cholesterol synthesis
Rates of liver cholesterol synthesis were measured in 16- to 24-week-old
FASKOL and wt littermates during the early light cycle after a 2 hr fast on
the various dietary regimens (4–5 mice per genotype per dietary treatment
group) using 3H-labeled water as previously described (Shimano et al.,
1996). Each animal was injected intraperitoneally with 50 mCi of [3H]-water
in 0.2 ml of saline. One hour after injection, 300–500 µl of blood was drawn
from the inferior vena cava to determine the plasma [3H]-water-specific ac-
tivity in duplicate. The livers were then removed, and 200–300 mg portions
were processed as previously described (Dietschy and Spady, 1984). The
rates of cholesterol synthesis were calculated as moles of 3H-radioactivity320incorporated into digitonin-precipitable sterols (DPS) per hour per gram of
tissue (Spady and Dietschy, 1983).
Quantitative RT-PCR-based gene expression
Total RNA was extracted with TRIzol reagent (Invitrogen). There was no
effect of genotype on RNA yields. After treatment with DNaseI, 1 g of total
RNA was reverse transcribed with an oligo-dT primer, and then quantitative
PCR was performed with the ABI Prism7700 PCR instrument (Applied Bio-
systems) using the TaqMan Universal PCR Master Mix reagent kit. Each
assay included a negative control using RNA not subjected to reverse tran-
scription. Oligonucleotide primers and TaqMan probes were designed using
Primer Express software (Applied Biosystems). Sequences are shown in Table
S1. Amplification specificity was verified by assessing products on an aga-
rose gel and using a heat-dissociation protocol. Sequence-specific amplifi-
cation was detected with an increasing fluorescent signal of FAM (reporter
dye) during the amplification cycle. Coamplification of the mRNA for the
mouse ribosomal protein L32 was performed in all samples. Assays were
performed in triplicate and results normalized to L32 mRNA levels, which
were unaffected by genotype or diet. Message levels were also normalized
to another invariant internal control, acidic ribosomal phosphoprotein 36B4,
with similar results to that seen with L32.
Western blotting
Livers and skeletal muscle (gastrocnemius) were frozen and homogenized
at 4°C as described previously (Kerouz et al., 1997). Thirty micrograms of
protein were resolved on a 10% SDS-polyacrylamide gel, electrotransferred
onto PVDF membranes (Amersham). Membranes were incubated with rab-
bit anti-mouse phospho-Akt (recognizing phosphorylated Akt at serine 473,
Cell Signaling 9271) and rabbit anti-mouse phospho-GSK3β (recognizing
phosphorylated GSK3b at serine 9, Cell signaling 9336) at 1:1000 dilution
at 4°C overnight, followed by secondary antibody incubation at 1:7500 dilu-
tion for 1 hr. Phospho-Akt- and phospho-GSK3β-specific bands were de-
tected by chemiluminescence (ECL kit, Amersham), then membranes were
stripped and reprobed with rabbit anti-mouse pan-Akt (recognizing total Akt
protein, Cell Signaling 9272) and rabbit anti-mouse pan-GSK3β (recognizing
total GSK3β protein, Cell Signaling 9332) also at 1:1000 dilution at 4°C
overnight. Reprobing with anti-actin antibody (Sigma, A2066) was per-
formed to ensure equal loading of protein in all lanes.
Statistical analyses
Values are expressed as mean ± standard error of the mean (SEM). Statisti-
cal comparisons were performed using an unpaired, two-tailed Student’s t
test (when two groups were analyzed) or analysis of variance (ANOVA). If
the overall F was found to be significant for the latter, comparisons between
means were made using appropriate post-hoc tests.
Supplemental data
Supplemental data include four figures and one table and can be found
with this article online at http://www.cellmetabolism.org/cgi/content/full/1/
5/309/DC1/.
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